Suminat 25 mg (Sumatriptan)

Product Overview

n

Suminat 25 mg is a prescription medication formulated to treat acute migraine attacks in adults. Manufactured by Sun Pharmaceutical Industries Ltd, each strip contains a single 25 mg tablet of sumatriptan succinate, a well‑studied serotonin receptor agonist. The product is packaged for convenient use, with available pack sizes of 10, 30, or 60 tablets, allowing patients to obtain an appropriate supply for ongoing therapy. This formulation is intended for oral administration and should be taken at the first sign of a migraine headache.

nn

What is Suminat 25 mg?

n

Suminat belongs to the class of triptamine derivatives known as 5‑HT_1B/1D receptor agonists. The active ingredient, sumatriptan, works by constricting dilated cranial blood vessels and inhibiting the release of inflammatory neuropeptides that are implicated in migraine pathophysiology. Although the full chemical name is often omitted in patient‑facing literature, the drug is commonly referred to simply as sumatriptan. For more detailed scientific information, you may refer to the <a href=”https://www.ncbi.nlm.nih.gov/books/NBK538777/”>National Center for Biotechnology Information</a> resources on sumatriptan.

nn

Uses and Benefits

n

Clinicians prescribe Suminat 25 mg primarily for the rapid alleviation of migraine symptoms, including throbbing head pain, nausea, photophobia (sensitivity to light), and phonophobia (sensitivity to sound). When taken early in the attack, many patients experience a reduction in pain intensity within two hours, enabling a quicker return to daily activities. The 25 mg strength is often selected for patients who require a lower dose due to cardiovascular considerations or who experience side effects at higher strengths. In addition to acute treatment, Suminat can be used in combination with other migraine therapies under medical supervision, providing flexibility in management strategies.

nn

How It Works

n

The therapeutic effect of Suminat stems from its ability to bind selectively to serotonin receptors (5‑HT_1B and 5‑HT_1D) located on endothelial cells of cerebral vessels and on peripheral trigeminal nerve terminals. This binding leads to vasoconstriction of the intracranial vasculature and suppression of neuropeptide release, particularly calcitonin gene‑related peptide (CGRP). By interrupting the cascade of events that underlie migraine pain, Suminat helps restore normal neuronal activity and reduces the severity of the headache. The onset of action typically occurs within 15‑30 minutes after oral ingestion, making it suitable for early intervention.

nn

Dosage Guidelines

n

For most adults, the recommended initial dose of Suminat 25 mg is one tablet taken at the onset of a migraine attack. If the headache persists or recurs, a second tablet may be administered after a minimum interval of 2 hours, provided the total daily dose does not exceed 50 mg (i.e., two tablets). The maximum recommended dose for any 24‑hour period is 200 mg, which generally corresponds to four 50 mg tablets; however, the 25 mg formulation limits the maximum to two tablets (50 mg) within 24 hours. Patients should not use Suminat more frequently than prescribed, and they should avoid taking additional doses if they have already reached the daily limit. It is advisable to consult a healthcare professional before adjusting the dose, especially for individuals with cardiovascular risk factors.

nn

Side Effects

n

Like all medications, Suminat 25 mg can cause adverse effects, although most are mild and transient. Common side effects include sensations of warmth or tingling, mild abdominal discomfort, and dizziness. Less frequently, patients may experience chest tightness, shortness of breath, or elevated blood pressure, which warrant immediate medical attention. Rare but serious reactions such as serotonin syndrome, allergic responses, or coronary artery spasm require urgent evaluation. A comprehensive list of reported side effects can be reviewed on the <a href=”https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/2022-0329s038lbl.pdf”>U.S. Food and Drug Administration labeling</a> for sumatriptan products.

nn

Warnings and Precautions

n

Suminat is contraindicated in patients with a history of cardiovascular disease, including angina pectoris, myocardial infarction, or uncontrolled hypertension, as well as in those with ergotamine‑type medication allergies. Prior to initiation, clinicians should assess cardiovascular risk and may order baseline cardiac evaluation for patients over 65 years of age or with comorbidities. Patients should be instructed to avoid concomitant use of selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs) within 24 hours of dosing to reduce the risk of serotonin syndrome. Alcohol consumption should be limited, and patients should be advised not to operate heavy machinery if they experience dizziness or drowsiness. Proper storage at room temperature, away from moisture and heat, preserves tablet integrity.

nn

Frequently Asked Questions

n

1. Can Suminat 25 mg be used for cluster headaches?
Clinically, sumatriptan is approved for migraine attacks and may be prescribed off‑label for cluster headaches under physician guidance. However, the 25 mg dose is not specifically indicated for cluster therapy, and alternative formulations such as nasal spray or injection are often preferred for rapid control.

nn

2. Is it safe to take Suminat with over‑the‑counter pain relievers?
Combining Suminat with non‑steroidal anti‑inflammatory drugs (NSAIDs) such as ibuprofen or aspirin is generally considered safe and may enhance pain relief. Patients should avoid using multiple migraine‑specific agents simultaneously without medical supervision.

nn

3. How long does the effect of Suminat last?
The analgesic effect of a single 25 mg tablet typically persists for up to two hours. If symptoms recur after this period, a second dose may be taken after a two‑hour interval, adhering to the maximum daily dose limits.

nn

4. Can pregnant or breastfeeding women use Suminat?
The safety of sumatriptan during pregnancy and lactation has not been fully established. Healthcare providers may consider it only when the expected benefit outweighs potential risks, and alternative treatments should be explored whenever possible.

nn

5. Where can I find more detailed prescribing information?
The complete prescribing information, including contraindications, drug interactions, and clinical trial data, is available through the <a href=”https://medlineplus.gov/druginfo/meds/a682150.html”>MedlinePlus</a> database and the official product label from Sun Pharmaceutical.

Related Products

• Vortidif 20 Mg (Vortioxetine)
• Vortidif 5 Mg (Vortioxetine)
• Pramipex 0.25 mg (Pramipexole)
• Mirtaz 30 Mg (Mirtazapine)
• Lurasidone 40 mg (Generic)
• Ropinirole 1 mg (Generic)
• Adesam 200 mg (Ademetionine/S-Adenosyl Methionine)
• Syncapone 100 mg (Levodopa/Carbidopa/Entacapone)
• Almotan 12.5 mg (Almotriptan)
• Cyclomune Eye Drop (Cyclosporin)
• Glypride 4 mg (Glimepiride)
• Natrise 15 mg (Tolvaptan)